337904-92-4

Usage

Chemical Properties

Off-white powder

InChI:InChI=1/C11H14N2O4/c1-11(2,3)17-10(16)13-8-4-7(9(14)15)5-12-6-8/h4-6H,1-3H3,(H,13,16)(H,14,15)

Upstream product

• 499-81-0 3,5-Pyridinedicarboxylic acid 
• 75-65-0 tert-butyl alcohol 
• 100-26-5 Pyridine-2,5-dicarboxylic acid 
• 375854-76-5 ethyl 5-((tert-butoxycarbonyl)amino)nicotinate 

Downstream Products

• 1008764-42-8 4-[3-(2-cyclohexylethoxy)benzoyl]-N-{5-[(methylsulfonyl)amino]pyridin-3-yl}piperazine-1-carboxamide 
• 1008775-40-3 N-(5-aminopyridin-3-yl)-4-[3-(2-cyclohexylethoxy)benzoyl]piperazine-1-carboxamide hydrochloride 
• 1008775-39-0 tert-butyl {5-[({4-[3-(2-cyclohexylethoxy)benzoyl]piperazin-1-yl}carbonyl)amino]pyridin-3-yl}carbamate 
• 914259-47-5 (3S,5R)-3-({9-[4-(tert-butyl-dimethyl-silanyloxy)-butyl]-9H-xanthen-9-ylmethyl}-carbamoyl)-5-(3,4-dimethoxybenzenesulfonylamino)-piperidine-1-carboxylic acid 9H-fluoren-9-ylmethyl ester 
• 914259-50-0 (3R,5S)-3-(3,4-dimethoxy-benzenesulfonylamino)-5-{[9-(4-morpholin-4-yl-butyl)-9H-xanthen-9-ylmethyl]-carbamoyl}-piperidine-1-carboxylic acid 9H-fluoren-9-ylmethyl ester 
• 914259-51-1 (3S,5R)-3-{[9-(3-carboxy-propyl)-9H-xanthen-9-ylmethyl]-carbamoyl}-5-(3,4-dimethoxy-benzenesulfonylamino)-piperidine-1-carboxylic acid 9H-fluoren-9-ylmethyl ester 
• 914259-52-2 (3R,5S)-3-(3,4-dimethoxy-benzenesulfonylamino)-5-{[9-(3-dimethylcarbamoyl-propyl)-9H-xanthen-9-ylmethyl]-carbamoyl}-piperidine-1-carboxylic acid 9H-fluoren-9-ylmethyl ester 
• 914259-48-6 (3R,5S)-3-(3,4-dimethoxy-benzenesulfonylamino)-5-{[9-(4-hydroxy-butyl)-9H-xanthen-9-ylmethyl]-carbamoyl}-piperidine-1-carboxylic acid 9H-fluoren-9-ylmethyl ester 
• 914259-49-7 (3R,5S)-3-(3,4-dimethoxy-benzenesulfonylamino)-5-{[9-(4-oxo-butyl)-9H-xanthen-9-ylmethyl]-carbamoyl}-piperidine-1-carboxylic acid 9H-fluoren-9-ylmethyl ester 
• 920296-45-3 (3S*,5R*)-5-tert-butoxycarbonylamino-piperidine-1,3-dicarboxylic acid 1-(9H-fluoren-9-ylmethyl)ester 

Relevant academic research and scientific papers

Chemical compounds

Provided herein are novel and useful compounds having a tryptase inhibition activity, pharmaceutical compositions comprising such compounds, and methods treating subjects suffering from a condition, disease, or disorder that can be ameliorated by the administration of an inhibitor of tryptase, e.g., asthma and inflammatory diseases, to name only a few.

MexAB-OprM-specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 1: Discovery and early strategies for lead optimization

The identification of a series of compounds that specifically inhibit efflux by the MexAB-OprM pump system in Pseudomonas aeruginosa is described. Synthesis and in vitro structure-activity relationships (SARs) are outlined. Early leads lacked activity in

DRUG DISCHARGE PUMP INHIBITORS

A medicament for preventive and/or therapeutic treatment of a microbial infection having an activity of eliminating resistance of a microorganism with acquired resistance to an antimicrobial agent, which comprises as an active ingredient a compound represented by the following general formula (I), a physiologically acceptable salt thereof, or a hydrate thereof: wherein R1 and R2 independently represent hydrogen atom, a halogen atom, carboxyl group and the like; J1 represents a 5- or 6-membered heteroaromatic ring; W1 represents -CH=CH-, -C≡C-, -CH2CH2- and the like; A1 represents phenylene group, pyridinediyl group, furandiyl group and the like; G1 represents oxygen atom, carbonyl group, ethynyl group and the like; p represents an integer of from 0 to 3; G2 represents phenylene group, furandiyl group, tetrahydrofurandiyl group and the like; G3 represents -CH2- or single bond; m and n represent an integer of 0 or 1; and Q1 represents an acidic group.